Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ALZN
stocks logo

ALZN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q3
FY2026Q4
--
--
-1.955
-45.69%
--
--
-2.060
+20.47%
--
--
-0.780
-91.77%
Estimates Revision
The market is revising No Change the revenue expectations for Alzamend Neuro, Inc. (ALZN) for FY2026, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -7.33%.
EPS Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-7.33%
In Past 3 Month
Wall Street analysts forecast ALZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALZN is 24.45 USD with a low forecast of 6.90 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ALZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALZN is 24.45 USD with a low forecast of 6.90 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.150
sliders
Low
6.90
Averages
24.45
High
42.00
Current: 2.150
sliders
Low
6.90
Averages
24.45
High
42.00
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$32 → $20
2025-03-17
Reason
Ascendiant Capital
Edward Woo
Price Target
$32 → $20
2025-03-17
Maintains
Strong Buy
Reason
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$35 → $32
2024-12-16
Reason
Ascendiant Capital
Edward Woo
Price Target
$35 → $32
2024-12-16
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Alzamend Neuro Inc (ALZN.O) is -0.37, compared to its 5-year average forward P/E of -20.26. For a more detailed relative valuation and DCF analysis to assess Alzamend Neuro Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-20.26
Current PE
-0.37
Overvalued PE
32.28
Undervalued PE
-72.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.82
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8.00
Undervalued EV/EBITDA
-21.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ALZN News & Events

Events Timeline

(ET)
2025-07-28
08:15:36
Alzamend Neuro to present at Military Health System Research Symposium
select
2025-07-23 (ET)
2025-07-23
08:06:53
Alzamend Neuro reports FY25 net cash provided by financing activities of $10.4M
select
2025-06-16 (ET)
2025-06-16
08:08:42
Alzamend Neuro announces final closing of $5M private placement
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-19Newsfilter
Alzamend Neuro Completes Clinical Phase of Phase II Trial for AL001 "Lithium in Brain" at Massachusetts General Hospital

  • Clinical Trial Completion: Alzamend Neuro has completed the clinical portion of its Phase II trial for AL001, a novel lithium-delivery system, aimed at improving treatment for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD.

  • Innovative Imaging Technology: The trial utilized a unique head coil technology for high-resolution lithium imaging, allowing for precise quantification of lithium in the brain, which may lead to better therapeutic efficacy and reduced side effects compared to conventional lithium salts.

  • Potential for Improved Safety: AL001 is designed to deliver lithium effectively while minimizing systemic exposure, potentially eliminating the need for therapeutic drug monitoring (TDM) and reducing risks of kidney and thyroid complications associated with traditional lithium treatments.

  • Future Developments: Alzamend plans to report topline data in the first quarter of 2026 and aims to initiate further Phase II clinical trials next year, building on the promising results of AL001's safety and efficacy profile.

[object Object]
Preview
9.0
11-19Benzinga
EXCLUSIVE: Alzamend Completes Clinical Phase of AL001 Study In Healthy Volunteers

  • Clinical Study Completion: Alzamend Neuro has completed the clinical portion of its first Phase 2 study of AL001, a novel oral therapeutic for Alzheimer's and other disorders, with topline data expected in early 2026.

  • Innovative Drug Delivery: AL001 aims to provide a safer lithium delivery system, potentially reducing systemic side effects and eliminating the need for frequent therapeutic drug monitoring, which is a challenge with traditional lithium salts.

  • Imaging Technology Utilization: The study employed advanced imaging technology to accurately quantify lithium in the brain, helping to establish optimal dosing for specific diseases.

  • Secondary Drug Candidate: Alzamend is also developing ALZN002, an immunotherapy targeting amyloid-beta proteins in Alzheimer's patients, with a Phase 1/2A trial already initiated to assess its safety and efficacy.

[object Object]
Preview
4.0
08-21Benzinga
Hewlett Packard Enterprise Set to Surge by 33%? Check Out 10 Leading Analyst Predictions for Thursday

  • Analyst Upgrades and Downgrades: Several Wall Street analysts have adjusted their price targets for various companies, with notable changes including I-Mab's target raised from $5 to $6 and Alzamend Neuro's target cut from $180 to $45.

  • Company Performance Ratings: Analysts maintained Buy ratings for I-Mab, DRDGOLD Limited, and The TJX Companies, while also upgrading Hewlett Packard Enterprise from Equal-Weight to Overweight.

  • Price Target Adjustments: Other significant adjustments include HC Wainwright raising DRDGOLD's target to $18.75, Susquehanna increasing Analog Devices' target to $300, and Piper Sandler reducing Civitas Resources' target to $52.

  • Current Stock Prices: As of Wednesday, I-Mab closed at $4.52, Alzamend Neuro at $2.26, and Lowe's at $257.14, reflecting the market's response to these analyst ratings and price target changes.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Alzamend Neuro Inc (ALZN) stock price today?

The current price of ALZN is 2.15 USD — it has increased 4.37 % in the last trading day.

arrow icon

What is Alzamend Neuro Inc (ALZN)'s business?

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

arrow icon

What is the price predicton of ALZN Stock?

Wall Street analysts forecast ALZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALZN is 24.45 USD with a low forecast of 6.90 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Alzamend Neuro Inc (ALZN)'s revenue for the last quarter?

Alzamend Neuro Inc revenue for the last quarter amounts to -2.70M USD, increased 180.57 % YoY.

arrow icon

What is Alzamend Neuro Inc (ALZN)'s earnings per share (EPS) for the last quarter?

Alzamend Neuro Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Alzamend Neuro Inc (ALZN)'s fundamentals?

The market is revising No Change the revenue expectations for Alzamend Neuro, Inc. (ALZN) for FY2026, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -7.33%.
arrow icon

How many employees does Alzamend Neuro Inc (ALZN). have?

Alzamend Neuro Inc (ALZN) has 4 emplpoyees as of December 05 2025.

arrow icon

What is Alzamend Neuro Inc (ALZN) market cap?

Today ALZN has the market capitalization of 8.17M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free